论文部分内容阅读
肺癌是全球范围内首位癌性死亡因素，发病率、死亡率高，预后欠佳。作为一种分子靶向治疗手段，表皮生长因子酪氨酸激酶抑制剂（EGFR?TKI）为EGFR突变的非小细胞肺癌（NSCLC）患者提供了一个新的治疗方向，且疗效显著，然而不可避免的是EGFR?TKI耐药问题。鉴于Ⅰ／Ⅱ期临床试验结果，目前有关EGFR?TKI耐药治疗策略包括：EGFR?TKI停药、继续EGFR?TKI、EGFR?TKI＋局部治疗、EGFR?TKI＋化疗、EGFR＋其他分子靶向药物治疗、EGFR?TKI再尝试、化疗、化疗＋其他分子靶向药物治疗、EGFR?TKI＋免疫治疗等，前景值得期待。本文就当前NSCLC患者EGFR?TKI耐药治疗进展作一综述。“,”Globally, lung cancer is the leading cause of cancer?related death with high morbidity, mortality and poor prognosis. The epidermal growth factor receptor?tyrosine kinase inhibitor( EGFR?TKI) , a means of molecularly targeted therapy, offers a novel ap?proach for the treatment of patients with NSCLC harboring EGFR mutation effectively. However, the problem of EGFR?TKI resistance ex?ists inevitably. A number of promising strategies based on different mechanisms have now been evaluated in phaseⅠ/Ⅱtrials. These in?clude EGFR?TKI discontinuation, EGFR?TKI continuing, EGFR?TKI+local treatment, EGFR+other molecularly targeted drugs, EGFR?TKI+chemotherapy, EGFR?TKI rechallenge, chemotherapy, chemotherapy+other molecularly targeted drugs and EGFR?TKI+immunother?apy. The purpose of this paper will draw a summary on the progress of treatments in patients with NSCLC harboring EGFR?TKI resistance.